39 results about "Adenine derivatives" patented technology

A novel nucleotide derivative, in case of existing as a member of a single-stranded sequence, undergoing a change in the fluorescent signal intendity depending on the corresponding base type in the partner strand with which the single-stranded sequence is hybridized, and which is a thymin / uracil derivative (1) emitting light most intensely when a confronting base in the partner strand with which the single-stranded nucleotide sequence is hybridized is adenine; a cytosine derivative (2) emitting light most intensely when the confronting base is guanine; an adenine derivative (3) emitting light most intensely when the confronting base is cytosine; a guanine derivative (4) emitting light most intensely when the confronting base is cytosine or thymine / uracil; and an adrnine derivative (5) emitting light most intensely when the confronting base is thymine / uracil / .

The present invention relates to compounds of formula (I):wherein R1 is C1-6alkylamino, or C1-6alkoxy; R2 is a group having the structure:n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the —(CH2)n— moiety at any carbon atom of the heterocycle; R3 is hydrogen, C1-8alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R1, R2, L1, Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.

Compounds of formula (I):wherein R1 is C1-6alkylamino, or C1-6alkoxy; R2 is a group having the structure:n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the —(CH2)n— moiety at any carbon atom of the heterocycle; R3 is hydrogen, C1-8alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.

The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro methodof inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediatedby a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

A novel nucleotide derivative, in case of existing as a member of a single-stranded sequence, undergoing a change in the fluorescent signal intensity depending on the corresponding base type in the partner strand with which the single-stranded sequence is hybridized, and which is (1) a thymine / uracil derivative emitting light most intensely when a confronting base in the partner strand with which the single-stranded nucleotide sequence is hybridized is adenine; (2) a cytosine derivative emitting light most intensely when the confronting base is guanine; (3) an adenine derivative emitting light most intensely when the confronting base is cytosine; and, (4) a guanine derivative emitting light most intensely when the confronting base is cytosine or thymine / uracil.

A novel nucleotide derivative showing a change in the fluorescent signal intensity depending on the corresponding base species of the counterpart chain of hybridization. And occurring as a member of a single-strand nucleotide sequence, where the corresponding base of the counterpart chain of the hybridization of the single-strand sequence is as followed:(1) which is a thymine / uracil derivative showing the most intense light emission in the case where the corresponding base is adenine; (2) which is a cytosine derivative showing the most intense light emission in the case where the corresponding base is guanine; (3) which is an adenine derivative showing the most intense light emission in the case where the corresponding base is cytosine; or (4) which is a guanine derivative showing the most intense light emission in the case where the corresponding base is cytosine or thymine / uracil.

The invention relates to a phosphonate prodrug of an adenine derivative and an application of the phosphonate prodrug to a medicine. Specifically, the invention relates to a compound having a generalformula (I) shown as in the description or optical isomer thereof, pharmaceutical salt, hydrate or solvate, and an application thereof to prepare a medicine for treating virus infectious diseases, especially hepatitis B (HBV) and aids (HIV). Substituents in the general formula (I) are defined same as in the description.

A nucleic acid base for hole transportation in DNAs which does not cause oxidative decomposition; and an artificial DNA molecule which can realize effective hole transportation in DNAs while maintaining the double spiral structure of the DNAs. Provided are: a nucleic acid which contains a benzodeazaadenine derivative base represented by the general formula (I):(wherein R1, R2, R3, R4, R5, and R6 each independently represents hydrogen, amino, mono (lower alkyl) amino, di (lower alkyl) amino, hydroxy, lower alkoxy, halogeno, cyano, mercapto, lower alkylthio, or aryl; and R7 and R8 each independently represents hydrogen or a group bonded to phosphoric acid);and a polynucleotide comprising the nucleic acid.

The present invention relates to a preparation method of adenine derivative. Said method includes the following steps: in non-protonic polar solvent, under the action of catalyst making adenine and phosphonate ester react at 50-150deg.C, then making after-treatment so as to obtain the invented product. The described catalyst at least contains one inorganic alkali and one organic alkali, the described inorganic alkali is selected from carbonate of alkali metal or sodium hydride, and the described organic alkali is selected from alcohol sodium or alcohol potassium of C1-C5.

The invention relates to the development of drugs intended for the prophylaxis and / or treatment of viral diseases caused, in particular, by herpes viruses. What are proposed are complex compounds of germanium having the general structural formula:Gex[AD][CA]y[AA]2   (1),where AD is a derivative of a nitrogenous base of the purine series that has antiviral activity and can be selected from guanine derivatives, such as acyclovir, valacyclovir, gancyclovir and pencyclovir, or from adenine derivatives, such as vidarabine; CA is a hydroxycarboxylic acid which can be selected from acids such as (but not limited to) citric acid, lactic acid and malic acid; AA is an amino acid which can be selected from various a-amino acids, such as arginine, gylcine, lysine and threonine, and where x=1-2, y=2-4 and z=0-2. Complex compounds of germanium have a high level of antiviral and immune-stimulating activity and are readily soluble in water. The above mentioned compounds are produced by producing an aqueous suspension of germanium dioxide, adding a hydroxycarboxylic acid, a derivative of a nitrogenous base of the purine series and, optionally, but preferably, an amino acid thereto, heating the mixture produced at a temperature of 40-100° C. for 3-14 hours while stirring and removing the water from the solution, thus producing a complex compound of germanium.

An adenine derivative series is prepared from bromobenze with borate radical through Dimroth rearranging reaction. Its advantage is high activity to suppress proinflammatory factor (tumor necrosis factor alpha) and splitting cell.

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

The invention relates to a calix[4]arene adenine derivative-oxidized graphene compound, a preparation method and applications thereof. The compound is formed by connecting oxidized graphene and calix[4]arene adenine derivatives through amido bonds. The preparation method comprises the following steps: (1) subjecting oxidized graphene to chloroformylation; (2) dissolving excess calix[4]arene adenine derivatives by an organic solvent, adding chloroformylated oxidized graphene powder, stirring for 6 to 96 hours at a room temperature to obtain a black particle suspension liquid, carrying out centrifugal separation, carrying out saturated salt water washing, adding distilled water, carrying out centrifugal separation, and drying to obtain black powder namely the calix[4]arene adenine derivative-oxidized graphene compound, which can be used to recognize, combine, and stabilize cancer gene promoter region G-quadrome. Compared with the prior art, the preparation technology is simple and easy to perform, and a novel method is provided to detect G-quadrome through biological macro-cycle molecules.

Disclosed are 9-deazaaadenine derivatives of the general formula (I)and pharmaceutically acceptable salts thereof, wherein A is OH or NH2, and B is H or NH2. Methods for treating, preventing and / or suppressing a Zika virus infection with the compounds disclosed are also provided. Pharmaceutical compositions comprising the disclosed compounds are also provided. Such pharmaceutical compositions may optionally contain one or more additional active agents.

Adenine derivatives substituted at the C2, N6, and N9 purine positions having antisenescent and combined photoprotective UVA / UVB effects. These substances are particularly suitable as anti-senescent and UV-photoprotective component in cosmetic preparations, plant protection preparations and in preparations for the treatment / application of tissue cultures.